Chondrosarcoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chondrosarcoma – Pipeline Review, H2 2017’, provides an overview of the Chondrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma

The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects

The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chondrosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Agios Pharmaceuticals Inc

Celgene Corp

Daiichi Sankyo Co Ltd

Epizyme Inc

Horizon Pharma Plc

Karyopharm Therapeutics Inc

Merck & Co Inc

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chondrosarcoma - Overview 7

Chondrosarcoma - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Chondrosarcoma - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Chondrosarcoma - Companies Involved in Therapeutics Development 21

Agios Pharmaceuticals Inc 21

Celgene Corp 21

Daiichi Sankyo Co Ltd 22

Epizyme Inc 22

Horizon Pharma Plc 23

Karyopharm Therapeutics Inc 23

Merck & Co Inc 24

Nektar Therapeutics 24

Novartis AG 25

Ono Pharmaceutical Co Ltd 25

Pfizer Inc 26

Chondrosarcoma - Drug Profiles 27

12-B80 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

aldoxorubicin hydrochloride - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

axitinib - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

DS-1001 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

enasidenib mesylate - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

galarmin - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

interferon gamma-1b - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

ivosidenib - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

nivolumab - Drug Profile 73

R&D Progress 74

NKTR-214 - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

pazopanib hydrochloride - Drug Profile 133

Product Description 133

Mechanism Of Action 133

R&D Progress 133

pembrolizumab - Drug Profile 142

R&D Progress 143

selinexor - Drug Profile 204

Product Description 204

Mechanism Of Action 204

R&D Progress 204

sirolimus - Drug Profile 227

Product Description 227

Mechanism Of Action 227

R&D Progress 227

sirolimus albumin-bound - Drug Profile 229

Product Description 229

Mechanism Of Action 229

R&D Progress 229

tazemetostat - Drug Profile 231

Product Description 231

Mechanism Of Action 231

R&D Progress 231

Chondrosarcoma - Dormant Projects 243

Chondrosarcoma - Discontinued Products 244

Chondrosarcoma - Product Development Milestones 245

Featured News & Press Releases 245

Nov 18, 2016: Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma 245

Appendix 247

Methodology 247

Coverage 247

Secondary Research 247

Primary Research 247

Expert Panel Validation 247

Contact Us 247

Disclaimer 248

List of Tables

List of Tables

Number of Products under Development for Chondrosarcoma, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products under Development by Universities/Institutes, H2 2017 10

Products under Development by Companies, H2 2017 11

Products under Development by Universities/Institutes, H2 2017 12

Number of Products by Stage and Target, H2 2017 14

Number of Products by Stage and Mechanism of Action, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Chondrosarcoma – Pipeline by Agios Pharmaceuticals Inc, H2 2017 21

Chondrosarcoma – Pipeline by Celgene Corp, H2 2017 22

Chondrosarcoma – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 22

Chondrosarcoma – Pipeline by Epizyme Inc, H2 2017 23

Chondrosarcoma – Pipeline by Horizon Pharma Plc, H2 2017 23

Chondrosarcoma – Pipeline by Karyopharm Therapeutics Inc, H2 2017 24

Chondrosarcoma – Pipeline by Merck & Co Inc, H2 2017 24

Chondrosarcoma – Pipeline by Nektar Therapeutics, H2 2017 25

Chondrosarcoma – Pipeline by Novartis AG, H2 2017 25

Chondrosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 26

Chondrosarcoma – Pipeline by Pfizer Inc, H2 2017 26

Chondrosarcoma – Dormant Projects, H2 2017 243

Chondrosarcoma – Discontinued Products, H2 2017 244

List of Figures

List of Figures

Number of Products under Development for Chondrosarcoma, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 13

Number of Products by Stage and Top 10 Targets, H2 2017 13

Number of Products by Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports